Bonus Rantz: Why "Personalized" Skincare Is Mostly a MARKETING Ploy

Most antioxidants quit after one job. Methylene blue doesn't, and that's the pitch Young Goose founder Amitay Eshel makes in this conversation about where longevity skincare is actually headed.

Eshel walks through why his brand maps every product to the 12 hallmarks of skin aging instead of building around a single molecule, the way he says most companies do when they're built to raise money and sell. The bigger reveal is about personalization. Eshel argues that truly custom skincare formulas are a marketing ploy, since FDA rules require formulas to be incubated and tested before they can be sold. The real personalization, he says, is the protocol, not the bottle, which matters for people in overcast climates like Washington who skip sunscreen and assume they're fine.

This interview covers Young Goose, biohacking and longevity skincare, methylene blue, copper peptides, exosomes, FDA regulation versus European marketing rules, and how your skin responds to your geolocation. Eshel also breaks down entry points into the brand, from the blue peptide spray he calls the first clinical strength methylene blue product on the market to the higher-end Vampire Exosomes at $285.

0:00 How Young Goose is different in a saturated market
2:18 Regional skin health and the Washington sunscreen problem
4:18 The truth about "personalized" skincare
5:15 US vs Europe on regulation and marketing
6:39 Where to start with the brand
7:18 What methylene blue actually does

Like and subscribe for conversations the rest of the media won't bother to have.

#Skincare #Longevity #Biohacking #MethyleneBlue #YoungGoose #AntiAging #JasonRantz #Wellness